Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176037
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCondom, Maria-
dc.contributor.authorMussetti, Alberto-
dc.contributor.authorMaluquer, Clara-
dc.contributor.authorParody, Rocío-
dc.contributor.authorGonzález Barca, Eva-
dc.contributor.authorArnan, Montserrat-
dc.contributor.authorAlbasanz Puig, Adaia-
dc.contributor.authorPomares, Helena-
dc.contributor.authorSalas, Maria Queralt-
dc.contributor.authorCarro, Itziar-
dc.contributor.authorPeña, Marta-
dc.contributor.authorClapes, Victòria-
dc.contributor.authorBaca Cano, Cristina-
dc.contributor.authorOliveira Ramos, Ana Carla-
dc.contributor.authorSanz Linares, Gabriela-
dc.contributor.authorMoreno González, Gabriel-
dc.contributor.authorMercadal, Santiago-
dc.contributor.authorBoqué Genovard, Concepción-
dc.contributor.authorGudiol González, Carlota-
dc.contributor.authorDomingo Domènech, Eva-
dc.contributor.authorSureda, Anna-
dc.date.accessioned2021-04-07T07:59:40Z-
dc.date.available2021-04-07T07:59:40Z-
dc.date.issued2021-03-03-
dc.identifier.urihttp://hdl.handle.net/2445/176037-
dc.description.abstractBackground: Clinical outcomes of novel coronavirus 2019 disease (COVID-19) in onco-hematological patients are unknown. When compared to non-immunocompromised patients, onco-hematological patients seem to have higher mortality rates. Aims: We describe the characteristics and outcomes of a consecutive cohort of 24 onco-hematological patients with COVID-19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. Methods and results: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID-19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22-82) years. Median follow-up in survivors was 14 (9-28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D-dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID-19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID-19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (-55%) and chemotherapy sessions (-19%). A significant increase in phone visits was reported (+581%). Conclusion: COVID-19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherWiley Periodicals LLC.-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/cnr2.1358-
dc.relation.ispartofCancer Reports, 2021-
dc.relation.urihttps://doi.org/10.1002/cnr2.1358-
dc.rightscc by (c) Condom et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationCOVID-19-
dc.subject.classificationOncologia-
dc.subject.classificationMalalties hematològiques-
dc.subject.otherCOVID-19-
dc.subject.otherOncology-
dc.subject.otherHematologic diseases-
dc.titleThe direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2021-03-25T07:52:51Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33656801-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cnr2.1358.pdf1.41 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons